MRK Stock Overview
Operates as a science and technology company in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for MRK from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €138.20 |
| 52 Week High | €177.00 |
| 52 Week Low | €136.10 |
| Beta | 0.72 |
| 1 Month Change | -2.50% |
| 3 Month Change | -11.15% |
| 1 Year Change | -2.19% |
| 3 Year Change | -38.63% |
| 5 Year Change | 31.24% |
| Change since IPO | 791.09% |
Recent News & Updates
Recent updates
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
Dec 16
Some Shareholders Feeling Restless Over Merck KGaA's (ETR:MRK) P/E Ratio
Oct 18Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?
Sep 05Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly
Jul 24Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E
Jul 03Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price
May 22Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20
Apr 26Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20
Apr 04Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20
Mar 18We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
Feb 07There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price
Jan 17Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price
Dec 27Shareholder Returns
| MRK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -2.5% | -2.6% |
| 1Y | -2.2% | -15.6% | 6.9% |
Return vs Industry: MRK exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: MRK underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MRK's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 62,255 | Belen Garijo Lopez | www.merckgroup.com/en |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | €60.09b |
| Earnings (TTM) | €2.70b |
| Revenue (TTM) | €20.96b |
22.3x
P/E Ratio2.9x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €20.96b |
| Cost of Revenue | €8.64b |
| Gross Profit | €12.33b |
| Other Expenses | €9.63b |
| Earnings | €2.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 06, 2025
| Earnings per share (EPS) | 6.20 |
| Gross Margin | 58.80% |
| Net Profit Margin | 12.86% |
| Debt/Equity Ratio | 37.8% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Merck KGaA is covered by 60 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Odile Rundquist | Baader Helvea Equity Research |